Gene Sequencing Giant Tries To Use Patents To Block Rising Star's Pocket-Sized Unit From US
from the anti-innovation dept
Last year, Techdirt wrote about how one of the most significant breakthroughs in the field of genomics is already embroiled in a nasty patent battle. But it's not just the fundamental techniques in this field that are being held back by selfish attempts to "own" key technologies. An article in the MIT Technology Review reports that the dominant manufacturer of DNA sequencing machines, Illumina, is trying to use patents to throttle an upstart rival:
Illumina said today it would try to block commercial sales of a disruptive new DNA sequencing instrument developed by a high-flying British rival, Oxford Nanopore.
Oxford Nanopore denies that it is infringing on any patent that Illumina controls, but needs to be able to prove that not just once, but twice. As well as suing in the courts, Illumina is trying to use the International Trade Commission (ITC) loophole that Techdirt has been warning about for many years now. The ITC does not award damages, but can impose injunctions that block the import of items it deems infringing. And that's precisely what Illumina wants, in order to stop the British Oxford Nanopore from challenging it in the US with its new technology, which offers important advantages over Illumina's systems:
In a patent lawsuit [pdf] and a separate complaint [pdf] with the U.S. International Trade Commission, Illumina said the British company's cutting-edge DNA sequencing devices contain stolen ideas and should be stopped at the docks.Illumina's refrigerator-sized instruments are fast and accurate (see "Why Illumina Is Number One"). But because it works differently, Oxford's MinION, as the device is called, is small enough to be portable (it's about the size of a cell phone) and reads out very long stretches of DNA.
According to the MIT Technology Review article, which gives more details on how the nanopore technology works, more than a thousand teams are already using Oxford Nanopore's pocked-sized sequencing unit. It offers capabilities that Illumina not only cannot match but is unlikely to match any time soon:
Although it's slower and less accurate than Illumina's instruments, nanopore technology threatens to become a competitor as scientists find entirely new applications for it like sequencing Ebola viruses and diagnosing patients from a makeshift lab in Guinea.In asking U.S. trade officials to investigate Oxford and possibly bar imports of the MinION to the U.S., Illumina could anger researchers, since no comparable technology is available. Illumina has never announced plans to sell a nanopore product of its own.
So, rather than competing by launching its own equivalent product, a big, successful company that dominates a market is trying to use legal actions to squash an exciting new technology before it becomes a serious threat. In other words, yet another case of patents being used not to innovate, for the benefit of the public, but to stifle innovation, solely for the benefit of the current market leader.
Follow me @glynmoody on Twitter or identi.ca, and +glynmoody on Google+
Thank you for reading this Techdirt post. With so many things competing for everyone’s attention these days, we really appreciate you giving us your time. We work hard every day to put quality content out there for our community.
Techdirt is one of the few remaining truly independent media outlets. We do not have a giant corporation behind us, and we rely heavily on our community to support us, in an age when advertisers are increasingly uninterested in sponsoring small, independent sites — especially a site like ours that is unwilling to pull punches in its reporting and analysis.
While other websites have resorted to paywalls, registration requirements, and increasingly annoying/intrusive advertising, we have always kept Techdirt open and available to anyone. But in order to continue doing so, we need your support. We offer a variety of ways for our readers to support us, from direct donations to special subscriptions and cool merchandise — and every little bit helps. Thank you.
–The Techdirt Team
Filed Under: dna sequencing, genomics, injunction, itc, itc loophole, patents
Companies: illumnia, oxford nanopore
Reader Comments
Subscribe: RSS
View by: Time | Thread
[ link to this | view in chronology ]
Silly
Please, if Illumina gets all the competition blocked they don't need to care who they anger, because they're the only game in town...which is exactly what they want.
[ link to this | view in chronology ]
[ link to this | view in chronology ]
[ link to this | view in chronology ]
[ link to this | view in chronology ]
Re:
The next quarter is all that matters anymore.
[ link to this | view in chronology ]
All the more curious
[ link to this | view in chronology ]
Re: All the more curious
How did it skip this step and move right into blocking sales and distribution of a product? Illumina obviously knew how the product worked right from the initial development phases. The product is already in use; why are they rent seeking after the fact instead of during the development and production process, since they were involved there?
[ link to this | view in chronology ]
This is interesting...
https://twitter.com/Erika_Check/status/707551785859178498
Tony.
[ link to this | view in chronology ]
Re: This is interesting...
[ link to this | view in chronology ]
[ link to this | view in chronology ]
Not fair
[ link to this | view in chronology ]
Re: Not fair
This is nonsense.
You don't patent the size of the machine. You patent how it works. The two machines are orthognal technologies, and operate completely differently.
[ link to this | view in chronology ]
The problem in a nutshell
Um - yeah. People seem to think you can own ideas, and patent attorneys encourage such thinking as they get paid regardless of how your application goes. Who knows? Maybe the USPTO rubber stamp will work in your favor?
[ link to this | view in chronology ]